General
Preferred name
ETRYPTAMINE
Synonyms
Alpha-ethyltryptamine ()
NSC-88061 ()
.alpha.et ()
RO 3-1932 ()
Monase ()
Etriptamina ()
NSC-63963 ()
U-17312E ()
ETRYPTAMINE ACETATE ()
.alpha.-Ethyltryptamine ()
.alpha.-Ethyltryptamine (exempt preparation) ()
P&D ID
PD008790
CAS
2235-90-7
14030-13-8
29854-42-0
Tags
available
drug
drug candidate
Drug Status
withdrawn
approved
investigational
illicit
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Developed in the 1960's for use as an antidepressant before market withdrawal in 1962. ;
MOA
The mechanism of action responsible for its antidepressant activity was believed to lie in its ability to inhibit monoamine oxidase, while its stimulant activity on the central nervous system appeared to result from its structural similarity to indole-based psychedelics. [5] ; ; Research discovered αET to be both a monoamine oxidase inhibitor and a potent monoamine releasing agent capable of serotonergic neurotoxicity. [3]; ; The ability to release serotonin was linked to αET's MDMA like properties. [2] αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
9
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
NPC Screening Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
188.13
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
2.45
TPSA
41.81
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
ATC
N
Source data

